
Medicine & Healthcare
By TrendScope Daily Staff · October 29, 2026
The FDA has approved an amendment that lets Paradromics recruit participants for its brain-computer interface study from anywhere in the continental United States, the company announced on October 26, removing a geographic barrier that had limited enrollment to people living within roughly a four-hour drive of one of three participating hospitals.
What Changed This Week
The change applies to the Connect-One Early Feasibility Study, the clinical trial evaluating Paradromics’ Connexus brain-computer interface (BCI). Previously, prospective participants had to live close enough to one of the study’s three sites — UC Davis Health in Sacramento, Mass General Brigham in Boston, or University of Michigan Health in Ann Arbor — to make the frequent visits the study requires. With the FDA’s sign-off on the protocol amendment, that distance requirement is gone, though every other eligibility criterion still applies, and participants must still be able to travel to a study site for required visits.
Inside the Connexus Implant
Connexus is a fully implantable device built around a high-density microelectrode array that records electrical activity directly from the brain. A transceiver placed in the chest relays those signals wirelessly through the skin to an external receiver, which translates neural activity into commands a computer can use. The goal of Connect-One is to test whether that pipeline can restore speech and give people with severe motor impairment a way to control a computer, over a long-term follow-up period of roughly six years per participant. The FDA approved the investigational device exemption that allowed the study to begin in November 2025, and Paradromics says it was the first company to win that approval for speech restoration using a fully implantable BCI.
A Patient Already Communicating
The study’s first participant, a woman from Michigan who has difficulty speaking because of motor neuron disease, received her implant at University of Michigan Health in June 2026 in a procedure led by neurosurgeon Dr. Matthew Willsey. According to Paradromics, she is now using the device to communicate. Dr. David M. Brandman, the study’s lead principal investigator, based at UC Davis Health, has described the implant as reflecting decades of progress across the broader intracortical BCI research community rather than a single company’s breakthrough in isolation.
“Being able to recruit from anywhere in the continental U.S. is an important step in the field of brain-computer interfaces.”
— Dr. David M. Brandman, Lead Principal Investigator, Connect-One study
Why Geography Mattered
Early feasibility studies for implantable devices are typically small and slow to enroll, in part because they require participants to live near a handful of specialized surgical and research centers. For a condition like motor neuron disease, where the population of eligible patients is already limited and often becomes less mobile over time, a four-hour driving radius around three hospitals could exclude many of the people the study is designed to help. William J. Marks Jr., Paradromics’ chief clinical officer, framed the amendment as a deliberate tradeoff the company is still working through operationally: “Our priority is to expand access while maintaining the highest standards of patient safety and continuity of care,” he said. Participants who live far from a study site and receive primary care elsewhere must now agree to let their own clinicians coordinate with the study team, and each site’s institutional review board will spend the coming months working out how to support people who travel long distances for screening, implantation and years of follow-up visits.
What Comes Next
Connexus remains an investigational device under U.S. law, meaning it isn’t approved for general use outside the clinical trial. Paradromics describes Connect-One as the first of several planned clinical applications for its BCI platform, building toward the kind of long-term clinical and support infrastructure that intracortical implants will need if they’re ever used more broadly. For now, the immediate significance is narrower but concrete: a nationwide applicant pool for a trial that has already shown one patient regaining a way to communicate, and three academic hospitals now preparing to screen candidates from well beyond their usual referral areas.
Readers curious about the broader science behind devices like Connexus may enjoy The Future of the Mind Michio Kaku book, a popular-science look at the neurotechnology reshaping how doctors think about the brain.
As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.